• Pacira Completes Acquisition of MyoScience, Advancing Leadership in Non-opioid Pain Management with FDA-approved ioveraº System

    • April 11, 2019
    • Posted By : admin
    • 0 Comment
    •   49 views

    Pacira BioSciences, Inc. (“Pacira”) (NASDAQ:PCRX) today announced that it has completed its previously announced acquisition of MyoScience, Inc. (“MyoScience”), a privately held medical technology company. This acquisition advances the company’s leadership in non-opioid pain management by adding the FDA-approved ioveraº system to the Pacira commercial offering.

    The ioveraº system is a novel, non-opioid treatment that alleviates pain through a mechanism known as cryoanalgesia, which applies intensely focused cold therapy to a specific nerve to interrupt its ability to transmit a pain signal. Results can be felt immediately after ioveraº treatment with pain relief that can last three months, and in some cases longer, as the nerve regenerates over time.

    “This acquisition marks another step forward in the Pacira commitment to fighting our nation’s opioid crisis by offering patients and healthcare providers innovative therapies to reduce or eliminate the need for opioids,” said Dave Stack, chairman and chief executive officer of Pacira. “We are excited to add the ioveraº system to our commercial offering, and expect the combination of this innovative therapy alongside EXPAREL® to offer orthopedic surgery patients exceptional pain control and a potentially opioid-free postsurgical experience. We also believe ioveraº offers a novel approach for improving patients’ experience earlier on the neural pain pathway for persistent conditions, such as osteoarthritis.  We believe ioverao will benefit greatly from our financial strength, established corporate and commercial infrastructure, growing partnership network, including our substantial collaboration with Johnson & Johnson, and deep domain expertise in opioid-sparing enhanced recovery after surgery protocols.”

  49 views

You Might Also Like

No comments found

LEAVE COMMENT

Archive

Offers
error: Content is protected !!